These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 9037248)
1. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. de Isabella P; Palumbo M; Sissi C; Carenini N; Capranico G; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC; Zunino F Biochem Pharmacol; 1997 Jan; 53(2):161-9. PubMed ID: 9037248 [TBL] [Abstract][Full Text] [Related]
2. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632 [TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772 [TBL] [Abstract][Full Text] [Related]
4. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029 [TBL] [Abstract][Full Text] [Related]
5. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Hazlehurst LA; Krapcho AP; Hacker MP Biochem Pharmacol; 1995 Sep; 50(7):1087-94. PubMed ID: 7575665 [TBL] [Abstract][Full Text] [Related]
6. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains. Sissi C; Moro S; Zagotto G; Ellis M; Krapcho AP; Menta E; Palumbo M Anticancer Drug Des; 1999 Jun; 14(3):265-74. PubMed ID: 10500501 [TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. Leteurtre F; Kohlhagen G; Paull KD; Pommier Y J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892 [TBL] [Abstract][Full Text] [Related]
8. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987 [TBL] [Abstract][Full Text] [Related]
9. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles. Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066 [TBL] [Abstract][Full Text] [Related]
10. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Hazlehurst LA; Krapcho AP; Hacker MP Cancer Lett; 1995 May; 91(1):115-24. PubMed ID: 7750086 [TBL] [Abstract][Full Text] [Related]
11. Bis-substituted hydroxy-anthracenediones: DNA binding and biological activity. Palumbo M; Palù G; Gia O; Ferrazzi E; Gastaldi S; Antonello C; Meloni GA Anticancer Drug Des; 1987 Apr; 1(4):337-46. PubMed ID: 3450303 [TBL] [Abstract][Full Text] [Related]
12. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity. Sissi C; Capranico G; Menta E; Palumbo M Mol Pharmacol; 1996 Oct; 50(4):838-45. PubMed ID: 8863828 [TBL] [Abstract][Full Text] [Related]
14. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Fisher GR; Patterson LH Cancer Chemother Pharmacol; 1992; 30(6):451-8. PubMed ID: 1394801 [TBL] [Abstract][Full Text] [Related]
15. Characterization of anthracenediones and their photoaffinity analogs. Chou KM; Krapcho AP; Horn D; Hacker M Biochem Pharmacol; 2002 Mar; 63(6):1143-7. PubMed ID: 11931847 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform. Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, DNA binding, topoisomerase II inhibition and cytotoxicity of two guanidine-containing anthracene-9,10-diones. Routier S; Bernier JL; Catteau JP; Riou JF; Bailly C Anticancer Drug Des; 1998 Jul; 13(5):407-15. PubMed ID: 9702207 [TBL] [Abstract][Full Text] [Related]
18. Antitumor potential of aza-bioisosterism in anthracenedione-based drugs. Sissi C; Palumbo M Curr Top Med Chem; 2004; 4(2):219-30. PubMed ID: 14754455 [TBL] [Abstract][Full Text] [Related]
19. Molecular basis of the low activity of antitumor anthracenediones, mitoxantrone and ametantrone, in oxygen radical generation catalyzed by NADH dehydrogenase. Enzymatic and molecular modelling studies. Tarasiuk J; Mazerski J; Tkaczyk-Gobis K; Borowski E Eur J Med Chem; 2005 Apr; 40(4):321-8. PubMed ID: 15804531 [TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]